Table 1 Results of the cost-effectiveness analysis.

From: Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma

 

ECX

FOLFIRI

Cost ($)

Costs for PFS per cycle

 Chemotherapy

959.68

2,275.46

 Supportive drugs

652.42

1,223.30

 Hospital

33.37

62.56

 Test

173.29

173.29

 AE

17.92

11.48

 Total

1,836.68

3,746.09

Costs for PD per cycle

 Chemotherapy

2,275.46

959.68

 Supportive drugs

1,223.30

652.42

 Hospital

62.56

33.37

 Test

173.29

173.29

 AE

16.44

18.54

 Total

3,751.04

1,837.30

Costs for PFS state

8,499.92

18,481.71

Costs for PD state

15,313.21

6,501.98

Total costs

23,813.13

24,983.70

Incremental costs

 

1,170.57

Effectiveness(QALMs)

Effectiveness for PFS state

3.69

3.93

Effectiveness for PD state

2.45

2.12

Total effectiveness

6.14

6.06

Incremental effectiveness

0.08

 

Cost/Effectiveness

3,879.72

4,125.84

Incremental cost/effectiveness

 

Dominated

  1. AE, adverse event; PFS, progression-free survival; PD, progressive disease; QALM, quality-adjusted life month; ECX, epirubicin, cisplatin, and capecitabine; FOLFIRI, fluorouracil, leucovorin, and irinotecan.
Back to article page